JP2023509388A5 - - Google Patents
Info
- Publication number
- JP2023509388A5 JP2023509388A5 JP2022538307A JP2022538307A JP2023509388A5 JP 2023509388 A5 JP2023509388 A5 JP 2023509388A5 JP 2022538307 A JP2022538307 A JP 2022538307A JP 2022538307 A JP2022538307 A JP 2022538307A JP 2023509388 A5 JP2023509388 A5 JP 2023509388A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- composition according
- population
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168495A JP2024175144A (ja) | 2019-12-18 | 2024-09-27 | 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19217356 | 2019-12-18 | ||
| EP19217356.5 | 2019-12-18 | ||
| PCT/EP2020/087151 WO2021123255A1 (en) | 2019-12-18 | 2020-12-18 | Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168495A Division JP2024175144A (ja) | 2019-12-18 | 2024-09-27 | 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509388A JP2023509388A (ja) | 2023-03-08 |
| JP2023509388A5 true JP2023509388A5 (cg-RX-API-DMAC7.html) | 2023-12-26 |
Family
ID=68944537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538307A Pending JP2023509388A (ja) | 2019-12-18 | 2020-12-18 | 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス |
| JP2024168495A Pending JP2024175144A (ja) | 2019-12-18 | 2024-09-27 | 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168495A Pending JP2024175144A (ja) | 2019-12-18 | 2024-09-27 | 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス |
Country Status (14)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN116421720A (zh) * | 2023-04-26 | 2023-07-14 | 乔国梁 | 抗肿瘤联用细胞产品和抗肿瘤细胞产品 |
| CN118853565A (zh) * | 2024-09-14 | 2024-10-29 | 青岛华赛伯曼医学细胞生物有限公司 | 一种肿瘤浸润淋巴细胞的培养工艺 |
| CN120173875A (zh) * | 2024-11-08 | 2025-06-20 | 毕诺济(上海)生物技术有限公司 | 肿瘤浸润淋巴细胞的无滋养层一步培养方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103374548A (zh) * | 2012-04-27 | 2013-10-30 | 上海诺昊亚医学诊断技术有限公司 | 一种肿瘤浸润淋巴细胞的高效扩增培养液 |
| ES2980788T3 (es) * | 2014-04-10 | 2024-10-03 | H Lee Moffitt Cancer Ct & Res | Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva |
| EP4338799A3 (en) * | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| TWI826360B (zh) * | 2016-11-17 | 2023-12-21 | 美商艾歐凡斯生物治療公司 | 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法 |
| CA3081479A1 (en) * | 2017-11-06 | 2019-05-09 | Ludwig Institute For Cancer Research Ltd | Method for expansion of lymphocytes |
-
2020
- 2020-12-18 CA CA3161510A patent/CA3161510A1/en active Pending
- 2020-12-18 MX MX2022007416A patent/MX2022007416A/es unknown
- 2020-12-18 ES ES20838028T patent/ES2984777T3/es active Active
- 2020-12-18 CN CN202080087408.0A patent/CN114929861A/zh active Pending
- 2020-12-18 WO PCT/EP2020/087151 patent/WO2021123255A1/en not_active Ceased
- 2020-12-18 EP EP20838028.7A patent/EP4077640B1/en active Active
- 2020-12-18 PH PH1/2022/551495A patent/PH12022551495A1/en unknown
- 2020-12-18 IL IL293874A patent/IL293874B2/en unknown
- 2020-12-18 KR KR1020227024481A patent/KR20220119080A/ko active Pending
- 2020-12-18 BR BR112022011702A patent/BR112022011702A2/pt unknown
- 2020-12-18 JP JP2022538307A patent/JP2023509388A/ja active Pending
- 2020-12-18 DK DK20838028.7T patent/DK4077640T3/da active
- 2020-12-18 US US17/756,814 patent/US20230018646A1/en active Pending
- 2020-12-18 AU AU2020408201A patent/AU2020408201A1/en active Pending
-
2024
- 2024-09-27 JP JP2024168495A patent/JP2024175144A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Daher et al. | CAR‐NK cells: the next wave of cellular therapy for cancer | |
| Shin et al. | NK cell-based immunotherapies in cancer | |
| Atilla et al. | The black hole: CAR T cell therapy in AML | |
| Rohaan et al. | Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option | |
| CN107922925B (zh) | 用于自然杀伤细胞扩增的方法 | |
| Taniguchi et al. | Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy | |
| Pinchuk et al. | Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells | |
| CN102559600A (zh) | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 | |
| EP3770251A1 (en) | Method for producing natural killer cells | |
| Khammari et al. | Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients | |
| Premkumar et al. | TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma | |
| Cany et al. | Umbilical cord blood–derived cellular products for cancer immunotherapy | |
| WO2013167136A1 (en) | Improving adoptive cell therapy with interferon gamma | |
| JP2022524882A5 (cg-RX-API-DMAC7.html) | ||
| Guo et al. | Proliferation of highly cytotoxic human natural killer cells by OX40L armed NK-92 with secretory neoleukin-2/15 for cancer immunotherapy | |
| JP2021516666A5 (cg-RX-API-DMAC7.html) | ||
| Dashtsoodol et al. | Natural killer T cell-targeted immunotherapy mediating long-term memory responses and strong antitumor activity | |
| Tassi et al. | Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients | |
| Mosna | The immunotherapy of acute myeloid leukemia: A clinical point of view | |
| Li et al. | Back to the future: spatiotemporal determinants of NK cell antitumor function | |
| Li et al. | Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells | |
| Yang et al. | A new ex vivo method for effective expansion and activation of human natural killer cells for anti-tumor immunotherapy | |
| ES2383418T3 (es) | Agente celular antiangiogénico para la terapia del cáncer. | |
| Su et al. | Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells | |
| KR20240011756A (ko) | 종양 침윤 t-림프구(til)의 생산 방법 및 인간 종양 치료를 위한 세포 치료제로서의 이의 용도 |